萊美藥業(300006.SZ):擬參投廣東東納協同產業投資合夥企業
格隆匯3月5日丨萊美藥業(300006.SZ)公佈,爲進一步優化投資結構,提升投資價值,加速佈局醫藥健康產業鏈中高壁壘、高成長性戰略環節,公司擬與德摩諮詢(深圳)有限公司、廣州邁普再生醫學科技股份有限公司、廣州康臣藥業有限公司、丁駿和張適安簽署《合夥協議》,以自有資金參與投資廣東東納協同產業投資合夥企業(有限合夥)。本次投資完成後合夥企業認繳出資總額爲人民幣9,100萬元,其中公司將作爲該合夥企業的有限合夥人認繳出資4,000萬元,本次認繳完成後公司將持有東納協同43.9560%的合夥份額;東納協同資金僅定向用於認購/申購廣東東納私募基金管理有限公司所管理的廣東東納醫健創業投資合夥企業(有限合夥)合夥份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.